To circumvent the diminished therapeutic effect and cardiac toxicity associated with revumenib and the high percentages of TRAEs with BN104, the second‐generation menin inhibitor balamenib (ZE63‐0302), could be an effective therapeutic for clinicians to treat KMT2Ar AML. The gene discussed is MEN1; the disease is acute myeloid leukemia.